Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).
Sign Up to like & getrecommendations! Published in 2022 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.2c00213
Abstract: Lazertinib (YH25448) is a novel third-generation tyrosine kinase inhibitor (TKI) developed as a treatment for EGFR mutant non-small cell lung cancer. To better understand the nature of lazertinib inhibition, we determined crystal structures of lazertinib… read more here.
Keywords: lazertinib yh25448; lazertinib; inhibition; chemistry ... See more keywords
Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.
Sign Up to like & getrecommendations! Published in 2023 at "Lung cancer"
DOI: 10.2139/ssrn.4379580
Abstract: INTRODUCTION Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that provides a high level of selectivity for sensitizing and p.Thr790Met (T790M) EGFR mutations. We aimed to collect real-world data regarding… read more here.
Keywords: lung cancer; lazertinib; t790m; real world ... See more keywords